Urgent Call to Action: FDA Advisers Advocate for Inclusion of Highly Spreadable Subclade K Variant in Flu Vaccines to Protect Our Health!
An advisory committee for the Food and Drug Administration (FDA) voted on Thursday to recommend the inclusion of the flu viral strain known as subclade K in upcoming vaccines this fall. This recommendation aligns with a suggestion from the World Health Organization, as this variant is believed to have contributed to the reduced effectiveness of flu vaccines during the current season.
According to the Centers for Disease Control and Prevention (CDC), the effectiveness of this year’s flu vaccine ranged from 38% to 41% in preventing outpatient visits among children and adolescents, and 41% for preventing hospitalizations. For adults, the effectiveness was notably lower, ranging from 22% to 34% against outpatient visits, and around 30% against hospitalizations.
Despite these underwhelming numbers, the CDC emphasized that vaccination still provides valuable protection against influenza. The agency pointed out that vaccinations during the previous flu season helped prevent approximately 5 million medical visits, 180,000 hospitalizations, and 12,000 deaths. Moreover, the CDC estimates that, between October 1 and February 28, influenza accounted for at least 26 million illnesses, 340,000 hospitalizations, and 21,000 deaths in the U.S.
During the advisory committee meeting, Dr. Lisa Grohskopf, a medical officer at the CDC’s Influenza Division, emphasized that subclade K is currently the dominant flu variant in the Northern Hemisphere. The University of Minnesota’s Center for Infectious Disease Research and Policy noted that viruses often undergo mutations, making it difficult to predict which strains will circulate during the next flu season. Vaccines typically require about six months for development, which is why experts decide on their formulation earlier in the year.
As Arnold Monto, an epidemiologist at the University of Michigan and acting chair of the Vaccines and Related Biological Products Advisory Committee, explained, “We’ve had a very efficient meeting in a very complicated year where we were reminded about how difficult strain selection is. It’s a little bit of science, a little bit of luck.”
Subclade K is a newly identified subgroup of the H3N2 flu family, a strain that has affected humans for years, as reported by Yale Medicine. This variant has been linked to an early surge in flu cases across the U.S., Japan, the United Kingdom, and various European countries. Preliminary data from health officials in the U.K. suggest that subclade K may spread more easily than other variants, resulting in increased hospitalizations and a higher incidence of positive test results.
“This is the worst we have had in years and possibly decades regarding inpatient flu numbers and test positivity rates at hospitals,” Dr. Scott Roberts, an infectious disease specialist at Yale Medicine, remarked. However, he noted that there is no evidence indicating that subclade K is more severe than previous strains. The term “super flu” may stem from the high number of infections and hospital admissions, reflecting increased transmissibility rather than an increase in severity.
As we approach the upcoming flu season, experts urge the public to stay informed and consider vaccination as a critical step in protecting against the potentially severe impacts of influenza.
Tags: Flu, FDA, Vaccine, H3N2, CDC, Subclade K, Public Health, Influenza
Original Source: https://san.com/cc/fda-advisers-suggest-covering-highly-spreadable-subclade-k-variant-in-flu-vaccines/
Category :
Tags:
Publish Date: 2026-03-14 04:13:00
